Vilhonen, Johanna http://orcid.org/0000-0001-9912-7682
Vuopio, Jaana
Vahlberg, Tero
Gröndahl-Yli-Hannuksela, Kirsi
Rantakokko-Jalava, Kaisu
Oksi, Jarmo
Funding for this research was provided by:
Maud Kuistila Foundation (2018-0063F)
Suomen Lääketieteen Säätiö (2018-2136)
Competitive State Financing of the Expert Responsibility area of Turku University Hospital (13285, 13604)
Academy of Finland (308482)
Rauno ja Anne Puolimatka Foundation (2017)
Article History
Received: 20 December 2019
Accepted: 11 February 2020
First Online: 25 February 2020
Compliance with ethical standards
:
: JVi reports a travel grant from MSD, Gilead, and Nordic Society of Clinical Microbiology and Infectious Disease and lecture fee from MSD and the Finnish Medical Society Duodecim. JVu reports receiving lecture fees or travel support as lecturer from non-profit organizations (Nordic Society of Clinical Microbiology and Infectious Disease, the Finnish Society of Infectious Disease Research and the Finnish Medical Society Duodecim). JO has been a scientific advisor (review panel or advisory committee) to Gilead Sciences Finland, GlaxoSmithKline, MSD Finland, and Unimedic Pharma AB, received lecture honoraria from Gilead Sciences Finland, GlaxoSmithKline, MSD Finland, and received coverage for congress travel/accommodation expenses from Gilead, Grifols, and MSD. TV, KGYH, and KRJ report no conflict of interest.
: This registry study was approved by the Turku Clinical Research Centre.